

# Mario Luppi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2573260/publications.pdf>

Version: 2024-02-01

332  
papers

12,385  
citations

36303  
51  
h-index

34986  
98  
g-index

337  
all docs

337  
docs citations

337  
times ranked

13235  
citing authors

#	ARTICLE	IF	CITATIONS
1	Fatigue in newly diagnosed acute myeloid leukaemia: general population comparison and predictive factors. <i>BMJ Supportive and Palliative Care</i> , 2023, 13, e344-e351.	1.6	1
2	PEG-Asparaginase Single-Agent Rescue in an Advanced Case of Monomorphic Epitheliotropic Intestinal T Cell Lymphoma. <i>Journal of Gastrointestinal Cancer</i> , 2023, 54, 304-308.	1.3	0
3	Edmonton symptom assessment system global distress score and overall survival among patients with advanced cancer receiving early palliative care. <i>BMJ Supportive and Palliative Care</i> , 2023, 13, e735-e736.	1.6	0
4	Edmonton symptom assessment system Global Distress Score and overall survival in acute leukaemia. <i>BMJ Supportive and Palliative Care</i> , 2023, 13, e746-e748.	1.6	0
5	Automated capture-based NGS workflow: one thousand patients experience in a clinical routine framework. <i>Diagnosis</i> , 2022, 9, 115-122.	1.9	3
6	Chromosome 16 changes do not always come for good. <i>International Journal of Laboratory Hematology</i> , 2022, 44, 19-20.	1.3	0
7	Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real-life experience. <i>Hematological Oncology</i> , 2022, 40, 32-40.	1.7	10
8	GITMO Registry Study on Allogeneic Transplantation in Patients Aged ≥60 Years from 2000 to 2017: Improvements and Criticisms. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 96.e1-96.e11.	1.2	13
9	Genomic and clinical findings in myeloid neoplasms with PDGFRB rearrangement. <i>Annals of Hematology</i> , 2022, 101, 297-307.	1.8	7
10	Perceptions of Hope Among Bereaved Caregivers of Cancer Patients Who Received Early Palliative Care: A Content and Lexicographic Analysis. <i>Oncologist</i> , 2022, 27, e168-e175.	3.7	10
11	The Response to Oxidative Damage Correlates with Driver Mutations and Clinical Outcome in Patients with Myelofibrosis. <i>Antioxidants</i> , 2022, 11, 113.	5.1	6
12	Early Palliative Care in Acute Myeloid Leukemia. <i>Cancers</i> , 2022, 14, 478.	3.7	13
13	Linking COVID-19, monocyte activation and sepsis: MDW, a novel biomarker from cytometry. <i>EBioMedicine</i> , 2022, 75, 103754.	6.1	9
14	BTK Inhibitors Impair Platelet-Mediated Antifungal Activity. <i>Cells</i> , 2022, 11, 1003.	4.1	7
15	Physicians' Perceptions of Clinical Utility of a Digital Health Tool for Electronic Patient-Reported Outcome Monitoring in Real-Life Hematology Practice. Evidence From the GIMEMA-ALLIANCE Platform. <i>Frontiers in Oncology</i> , 2022, 12, 826040.	2.8	5
16	Indoleamine 2, 3-Dioxygenase 1 Mediates Survival Signals in Chronic Lymphocytic Leukemia via Kynurenine/Aryl Hydrocarbon Receptor-Mediated MCL1 Modulation. <i>Frontiers in Immunology</i> , 2022, 13, 832263.	4.8	6
17	The Role of T Cell Immunity in Monoclonal Gammopathy and Multiple Myeloma: From Immunopathogenesis to Novel Therapeutic Approaches. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5242.	4.1	7
18	Validation and functional characterization of GWAS-identified variants for chronic lymphocytic leukemia: a CRuCIAL study. <i>Blood Cancer Journal</i> , 2022, 12, 79.	6.2	1

#	ARTICLE	IF	CITATIONS
19	High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2022, 40, 3120-3131.	1.6	29
20	Two fatal cases of acute liver failure due to HSV-1 infection in COVID-19 patients following immunomodulatory therapies. <i>Clinical Infectious Diseases</i> , 2021, 73, e252-e255.	5.8	39
21	Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric-like GIMEMA LAL-308 trial. <i>American Journal of Hematology</i> , 2021, 96, 292-301.	4.1	21
22	Characterization of New ATM Deletion Associated with Hereditary Breast Cancer. <i>Genes</i> , 2021, 12, 136.	2.4	7
23	Nurse-Like Cells and Chronic Lymphocytic Leukemia B Cells: A Mutualistic Crosstalk inside Tissue Microenvironments. <i>Cells</i> , 2021, 10, 217.	4.1	19
24	Inflammatory Microenvironment and Specific T Cells in Myeloproliferative Neoplasms: Immunopathogenesis and Novel Immunotherapies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1906.	4.1	19
25	Adoptive Transfer of JC Virus-Specific T Lymphocytes for the Treatment of Progressive Multifocal Leukoencephalopathy. <i>Annals of Neurology</i> , 2021, 89, 769-779.	5.3	30
26	IRF4 modulates the response to BCR activation in chronic lymphocytic leukemia regulating IKAROS and SYK. <i>Leukemia</i> , 2021, 35, 1330-1343.	7.2	13
27	Cytomegalovirus reactivation after hematopoietic stem cell transplant with CMV prophylaxis: A monocentric retrospective analysis. <i>Journal of Medical Virology</i> , 2021, 93, 6292-6300.	5.0	3
28	Different semantic and affective meaning of the words associated to physical and social pain in cancer patients on early palliative/supportive care and in healthy, pain-free individuals. <i>PLoS ONE</i> , 2021, 16, e0248755.	2.5	5
29	iVar, an Interpretation-Oriented Tool to Manage the Update and Revision of Variant Annotation and Classification. <i>Genes</i> , 2021, 12, 384.	2.4	21
30	Ibrutinib interferes with innate immunity in chronic lymphocytic leukemia patients during COVID-19 infection. <i>Haematologica</i> , 2021, 106, 2265-2268.	3.5	6
31	A single-tube multiplex method for monitoring mutations in cysteine 481 of Bruton Tyrosine Kinase (BTK) gene in chronic lymphocytic leukemia patients treated with ibrutinib. <i>Leukemia and Lymphoma</i> , 2021, 62, 2018-2021.	1.3	2
32	Education of early palliative care specialists among hematologists and oncologists to address patients' rather than physicians' rights. <i>Annals of Hematology</i> , 2021, 100, 2857-2858.	1.8	3
33	Monocyte Distribution Width (MDW) as novel inflammatory marker with prognostic significance in COVID-19 patients. <i>Scientific Reports</i> , 2021, 11, 12716.	3.3	38
34	COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies. <i>British Journal of Haematology</i> , 2021, 195, 371-377.	2.5	56
35	Neoantigen-Specific T-Cell Immune Responses: The Paradigm of NPM1-Mutated Acute Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9159.	4.1	7
36	IRF4 L116R mutation promotes proliferation of chronic lymphocytic leukemia B cells inducing MYC. <i>Hematological Oncology</i> , 2021, 39, 707-711.	1.7	5

#	ARTICLE	IF	CITATIONS
37	How to Improve Prognostication in Acute Myeloid Leukemia with CBFB-MYH11 Fusion Transcript: Focus on the Role of Molecular Measurable Residual Disease (MRD) Monitoring. <i>Biomedicines</i> , 2021, 9, 953.	3.2	6
38	Need for integrating early palliative care with standard hematology care long before the allogeneic hemopoietic stem cells transplantation. <i>Annals of Hematology</i> , 2021, , 1.	1.8	2
39	Herpes Simplex Virus Re-Activation in Patients with SARS-CoV-2 Pneumonia: A Prospective, Observational Study. <i>Microorganisms</i> , 2021, 9, 1896.	3.6	28
40	Increased Plasma Levels of lncRNAs LINC01268, GAS5 and MALAT1 Correlate with Negative Prognostic Factors in Myelofibrosis. <i>Cancers</i> , 2021, 13, 4744.	3.7	9
41	Changes in Cancer Patients' and Caregivers' Disease Perceptions While Receiving Early Palliative Care: A Qualitative and Quantitative Analysis. <i>Oncologist</i> , 2021, 26, e2274-e2287.	3.7	13
42	Multiparametric Flow Cytometry for MRD Monitoring in Hematologic Malignancies: Clinical Applications and New Challenges. <i>Cancers</i> , 2021, 13, 4582.	3.7	28
43	Polymorphisms within the TNFSF4 and MAPKAPK2 Loci Influence the Risk of Developing Invasive Aspergillosis: A Two-Stage Case Control Study in the Context of the aspBIOmics Consortium. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 4.	3.5	5
44	Pre-existing cytopenia heralding de novo acute myeloid leukemia: uncommon presentation of NPM1-mutated AML in a single-center study. <i>Leukemia Research</i> , 2021, 111, 106747.	0.8	0
45	Early palliative/supportive care in acute myeloid leukaemia allows low aggression end-of-life interventions: observational outpatient study. <i>BMJ Supportive and Palliative Care</i> , 2021, , bmjspcare-2021-002898.	1.6	12
46	Notch2 Increases the Resistance to Venetoclax-Induced Apoptosis in Chronic Lymphocytic Leukemia B Cells by Inducing Mcl-1. <i>Frontiers in Oncology</i> , 2021, 11, 777587.	2.8	9
47	In Ph+BCR-ABL1P210+ acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent. <i>Leukemia</i> , 2020, 34, 929-931.	7.2	6
48	Early versus delayed palliative/supportive care in advanced cancer: an observational study. <i>BMJ Supportive and Palliative Care</i> , 2020, 10, e32-e32.	1.6	28
49	Immunomodulatory effect of ibrutinib: Reducing the barrier against fungal infections. <i>Blood Reviews</i> , 2020, 40, 100635.	5.7	29
50	Selective inhibition of PI3KÎ³ affects survival and proliferation of chronic lymphocytic leukemia B cells. <i>Leukemia and Lymphoma</i> , 2020, 61, 455-459.	1.3	1
51	Early Palliative Care: A Necessary Intervention for Patients Ineligible to Approved Potentially Life-saving CAR T-cell Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 201-202.	0.4	6
52	Independent Research on Cancer Pain Management in the Setting of Early Palliative Care: A Flywheel to Counteract General Opioid Misuse and Abuse. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 7097.	2.6	3
53	NPM1-Mutated Myeloid Neoplasms with <20% Blasts: A Really Distinct Clinico-Pathologic Entity?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8975.	4.1	26
54	Investigating the association between physicians self-efficacy regarding communication skills and risk of "burnout". <i>Health and Quality of Life Outcomes</i> , 2020, 18, 271.	2.4	32

#	ARTICLE	IF	CITATIONS
55	Epidemiology and clinical outcomes of latent tuberculosis infection in adults affected with acute leukemia or aplastic anemia: a retrospective single-center study. <i>Annals of Hematology</i> , 2020, 99, 2201-2203.	1.8	3
56	Ibrutinib Is a Newly Recognized Host Factor for the Definition of Probable Invasive Pulmonary Mold Disease, Based on Off-target Effects, Unrelated to Its B-cell Immunosuppressant Activity. <i>Clinical Infectious Diseases</i> , 2020, 71, 3265-3266.	5.8	4
57	COVID-19: more than a cytokine storm. <i>Critical Care</i> , 2020, 24, 549.	5.8	34
58	BTK Inhibition Impairs the Innate Response Against Fungal Infection in Patients With Chronic Lymphocytic Leukemia. <i>Frontiers in Immunology</i> , 2020, 11, 2158.	4.8	30
59	COVID-19 Pandemic and Cancer: The Importance of Early Palliative Care. <i>Oncologist</i> , 2020, 26, e2094-e2096.	3.7	1
60	Harnessing T Cells to Control Infections After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2020, 11, 567531.	4.8	10
61	Cancer treatment during the coronavirus disease 2019 pandemic: Do not postpone, do it!. <i>European Journal of Cancer</i> , 2020, 133, 29-32.	2.8	34
62	COVID-19: room for treating T cell exhaustion?. <i>Critical Care</i> , 2020, 24, 229.	5.8	18
63	Effects of Anti-vitamin k oral anticoagulants on bone and cardiovascular health. <i>European Journal of Internal Medicine</i> , 2020, 79, 1-11.	2.2	10
64	High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity. <i>International Journal of Hematology</i> , 2020, 112, 141-146.	1.6	2
65	Younger age at diagnosis of acute promyelocytic leukaemia is associated with better long-term cognitive functioning. <i>British Journal of Haematology</i> , 2020, 190, e304-e307.	2.5	1
66	Acute Myeloid Leukemia in Patients Living with HIV Infection: Several Questions, Fewer Answers. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1081.	4.1	10
67	Clinical Characteristics and Outcome of West Nile Virus Infection in Patients with Lymphoid Neoplasms: An Italian Multicentre Study. <i>HemaSphere</i> , 2020, 4, e395.	2.7	4
68	Acute promyelocytic leukaemia long-term survivors: higher fatigue and greater overall symptom burden. <i>BMJ Supportive and Palliative Care</i> , 2020, , bmjspcare-2020-002281.	1.6	1
69	Indoleamine 2,3-Dioxygenase Mediates Survival of Chronic Lymphocytic Leukemia B Cells through Aryl Hydrocarbon Receptor By Inducing Mcl1. <i>Blood</i> , 2020, 136, 19-19.	1.4	0
70	Validation of ELN2017 Risk Stratification in a Post-Hoc Analysis of the Prospective Biomarker-Based Gimema AML1310 Protocol. <i>Blood</i> , 2020, 136, 34-35.	1.4	0
71	T-cell large granular lymphocyte leukemia in solid organ transplant recipients: case series and review of the literature. <i>International Journal of Hematology</i> , 2019, 110, 313-321.	1.6	14
72	Mindfulness-Based stress reduction in early palliative care for people with metastatic cancer: A mixed-method study. <i>Complementary Therapies in Medicine</i> , 2019, 47, 102218.	2.7	22

#	ARTICLE	IF	CITATIONS
73	GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. <i>Blood</i> , 2019, 134, 935-945.	1.4	148
74	Breakthrough invasive fungal diseases in acute myeloid leukemia patients receiving mould active triazole primary prophylaxis after intensive chemotherapy: An Italian consensus agreement on definitions and management. <i>Medical Mycology</i> , 2019, 57, S127-S137.	0.7	14
75	Characterization and dynamics of specific T cells against nucleophosmin-1 (NPM1)-mutated peptides in patients with NPM1-mutated acute myeloid leukemia. <i>Oncotarget</i> , 2019, 10, 869-882.	1.8	25
76	Clinical differences in sarcoidosis patients with and without lymphoma: a single-centre retrospective cohort analysis. <i>European Respiratory Journal</i> , 2019, 54, 1802470.	6.7	10
77	Health-related quality of life, symptom burden, and comorbidity in long-term survivors of acute promyelocytic leukemia. <i>Leukemia</i> , 2019, 33, 1598-1607.	7.2	15
78	Overexpression of CD49d in trisomy 12 chronic lymphocytic leukemia patients is mediated by IRF4 through induction of IKAROS. <i>Leukemia</i> , 2019, 33, 1278-1302.	7.2	10
79	Rhodotorula infection in haematological patient: Risk factors and outcome. <i>Mycoses</i> , 2019, 62, 223-229.	4.0	17
80	NOTCH2 Contributes to Venetoclax Resistance in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2019, 134, 4280-4280.	1.4	3
81	A typical atypical chronic myeloid leukemia. <i>Clinical Case Reports (discontinued)</i> , 2018, 6, 915-916.	0.5	3
82	Is there a role for intervention radiology for the treatment of lower limb deep vein thrombosis in the era of direct oral anticoagulants? A comprehensive review. <i>European Journal of Internal Medicine</i> , 2018, 52, 13-21.	2.2	7
83	Dual inhibition of PI3K/mTOR signaling in chemoresistant AML primary cells. <i>Advances in Biological Regulation</i> , 2018, 68, 2-9.	2.3	16
84	Effectiveness of originator (Neupogen) and biosimilar (Zarzio) filgrastim in autologous peripheral blood stem cell mobilization in adults with acute myeloid leukemia: a single-center retrospective study. <i>Leukemia and Lymphoma</i> , 2018, 59, 225-228.	1.3	3
85	Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide. <i>Leukemia and Lymphoma</i> , 2018, 59, 423-433.	1.3	7
86	O blood type is a risk factor for upper gastrointestinal bleeding. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 48-50.	2.1	8
87	Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes. <i>Cancer</i> , 2018, 124, 1251-1259.	4.1	31
88	Angiopoietin-2 acts as a survival factor for chronic lymphocytic leukemia B cells throughout T cell receptor engagement. <i>Hematological Oncology</i> , 2018, 36, 372-375.	1.7	0
89	Minimal/Measurable Residual Disease Monitoring in NPM1-Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and Perspectives. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3492.	4.1	52
90	Novel Agents for Acute Myeloid Leukemia. <i>Cancers</i> , 2018, 10, 429.	3.7	21

#	ARTICLE	IF	CITATIONS
91	Immunophenotypic profile and clinical outcome of monoclonal B-cell lymphocytosis in kidney transplantation. <i>Clinical Transplantation</i> , 2018, 32, e13338.	1.6	5
92	Idelalisib impairs T-cell-mediated immunity in chronic lymphocytic leukemia. <i>Haematologica</i> , 2018, 103, e598-e601.	3.5	16
93	Pretreatment Health-Related Quality of Life Profile According to the EORTC QLQ-C30 in Patients with Myelodysplastic Syndromes (MDS): Analysis on 443 Lower-Risk MDS Patients. <i>Blood</i> , 2018, 132, 2293-2293.	1.4	1
94	The expression of endothelin-1 in chronic lymphocytic leukemia is controlled by epigenetic mechanisms and extracellular stimuli. <i>Leukemia Research</i> , 2017, 54, 17-24.	0.8	8
95	More About the Risk of Ibrutinib-associated Bleeding. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 326-327.	0.4	1
96	Successful Treatment of Kaposi Sarcoma-associated Herpesvirus Inflammatory Cytokine Syndrome After Kidney-Liver Transplant: Correlations With the Human Herpesvirus 8 miRNome and Specific T Cell Response. <i>American Journal of Transplantation</i> , 2017, 17, 2963-2969.	4.7	26
97	Multicenter Prospective Study for Laboratory Diagnosis of HHV8 Infection in Solid Organ Donors and Transplant Recipients and Evaluation of the Clinical Impact After Transplantation. <i>Transplantation</i> , 2017, 101, 1935-1944.	1.0	34
98	Liposomal amphotericin B (AmBisome®) at beginning of its third decade of clinical use. <i>Journal of Chemotherapy</i> , 2017, 29, 131-143.	1.5	26
99	BCR-ABL-specific T-cell therapy in Ph+ ALL patients on tyrosine-kinase inhibitors. <i>Blood</i> , 2017, 129, 582-586.	1.4	49
100	Detection of Fusarium-specific T cells in hematologic patients with invasive fusariosis. <i>Journal of Infection</i> , 2017, 74, 314-318.	3.3	7
101	Clinical Utility of Epstein-Barr Virus Viral Load Monitoring and Risk Factors for Posttransplant Lymphoproliferative Disorders After Kidney Transplantation: A Single-Center, 10-Year Observational Cohort Study. <i>Transplantation Direct</i> , 2017, 3, e182.	1.6	10
102	Anticancer drug-loaded quantum dots engineered polymeric nanoparticles: Diagnosis/therapy combined approach. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 107, 230-239.	4.0	23
103	Monoclonal Gammopathy of Undetermined Significance After Kidney Transplantation. <i>Transplantation</i> , 2017, 101, e337-e342.	1.0	15
104	LYMPHOPROLIFERATIVE SYNDROMES ASSOCIATED WITH HUMAN HERPESVIRUS-6A AND HUMAN HERPESVIRUS-6B. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2017, 10, 2018035.	1.3	9
105	Macitentan, a double antagonist of endothelin receptors, efficiently impairs migration and microenvironmental survival signals in chronic lymphocytic leukemia. <i>Oncotarget</i> , 2017, 8, 90013-90027.	1.8	5
106	Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia. <i>Oncotarget</i> , 2016, 7, 65968-65981.	1.8	84
107	Common Genetic Polymorphisms within NF- $\kappa$ B-Related Genes and the Risk of Developing Invasive Aspergillosis. <i>Frontiers in Microbiology</i> , 2016, 7, 1243.	3.5	13
108	All-trans retinoic acid (ATRA) in non-promyelocytic acute myeloid leukemia (AML): results of combination of ATRA with low-dose Ara-C in three elderly patients with NPM1-mutated AML unfit for intensive chemotherapy and review of the literature. <i>Clinical Case Reports (discontinued)</i> , 2016, 4, 1138-1146.	0.5	7



#	ARTICLE	IF	CITATIONS
109	A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study. <i>Haematologica</i> , 2016, 101, 1544-1552.	3.5	72
110	Reply to O. Corli et al and M. Lucchesi et al. <i>Journal of Clinical Oncology</i> , 2016, 34, 3580-3581.	1.6	0
111	Circulating functional T cells specific to human herpes virus 6 (HHV6) antigens in individuals with chromosomally integrated HHV6. <i>Clinical Microbiology and Infection</i> , 2016, 22, 893-895.	6.0	5
112	Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis. <i>Supportive Care in Cancer</i> , 2016, 24, 4487-4493.	2.2	9
113	Variability of Voriconazole Trough Levels in Haematological Patients: Influence of Comedications with cytochrome P450(<sc>CYP</sc>) Inhibitors and/or with <sc>CYP</sc> Inhibitors plus <sc>CYP</sc> Inducers. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2016, 118, 474-479.	2.5	34
114	Chronic and recurrent benign lymphadenopathy without constitutional symptoms associated with human herpesvirusâ€B reactivation. <i>British Journal of Haematology</i> , 2016, 172, 561-572.	2.5	6
115	The bone marrow represents an enrichment site of specific T lymphocytes against filamentous fungi. <i>Medical Mycology</i> , 2016, 54, 327-332.	0.7	2
116	Polymorphisms in Host Immunity-Modulating Genes and Risk of Invasive Aspergillosis: Results from the AspBIOmics Consortium. <i>Infection and Immunity</i> , 2016, 84, 643-657.	2.2	35
117	Randomized Trial of Low-Dose Morphine Versus Weak Opioids in Moderate Cancer Pain. <i>Journal of Clinical Oncology</i> , 2016, 34, 436-442.	1.6	145
118	Lenalidomide in chronic lymphocytic leukemia: the present and future in the era of tyrosine kinase inhibitors. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 97, 291-302.	4.4	12
119	CRLF2 overexpression identifies an unfavourable subgroup of adult B-cell precursor acute lymphoblastic leukemia lacking recurrent genetic abnormalities. <i>Leukemia Research</i> , 2016, 41, 36-42.	0.8	41
120	PEGylated siRNA lipoplexes for silencing of BLIMP-1 in Primary Effusion Lymphoma: In vitro evidences of antitumoral activity. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2016, 99, 7-17.	4.3	17
121	Evaluation of serum (1â†’3)-â†’-d-glucan clinical performance: kinetic assessment, comparison with galactomannan and evaluation of confounding factors. <i>Infection</i> , 2016, 44, 223-233.	4.7	27
122	Mucorales-Specific T Cells in Patients with Hematologic Malignancies. <i>PLoS ONE</i> , 2016, 11, e0149108.	2.5	40
123	Reversal of the glycolytic phenotype of primary effusion lymphoma cells by combined targeting of cellular metabolism and PI3K/Akt/ mTOR signaling. <i>Oncotarget</i> , 2016, 7, 5521-5537.	1.8	30
124	Antineoplastic effects of liposomal short interfering RNA treatment targeting BLIMP1/PRDM1 in primary effusion lymphoma. <i>Haematologica</i> , 2015, 100, e467-e470.	3.5	9
125	Immunologic evidence of a strong association between nonâ€<sc>H</sc>odgkin lymphoma and simian virus 40. <i>Cancer</i> , 2015, 121, 2618-2626.	4.1	22
126	Targeting neoplastic B cells and harnessing microenvironment: the â€double faceâ€ of ibrutinib and idelalisib. <i>Journal of Hematology and Oncology</i> , 2015, 8, 60.	17.0	49



#	ARTICLE	IF	CITATIONS
127	Combination antifungal therapy for invasive mould diseases in haematologic patients. An update on clinical data. <i>Journal of Chemotherapy</i> , 2015, 27, 1-12.	1.5	19
128	Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study). <i>Haematologica</i> , 2015, 100, 284-292.	3.5	64
129	Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia. <i>Haematologica</i> , 2015, 100, 253-262.	3.5	40
130	Philadelphia chromosome-positive Acute Lymphoblastic Leukemia. <i>Hematology</i> , 2015, 20, 618-619.	1.5	9
131	Differences among young adults, adults and elderly chronic myeloid leukemia patients. <i>Annals of Oncology</i> , 2015, 26, 185-192.	1.2	72
132	Nutlin-3 loaded nanocarriers: Preparation, characterization and in vitro antineoplastic effect against primary effusion lymphoma. <i>International Journal of Pharmaceutics</i> , 2015, 490, 85-93.	5.2	10
133	NPM1 mutations may reveal acute myeloid leukemia in cases otherwise morphologically diagnosed as myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. <i>Leukemia and Lymphoma</i> , 2015, 56, 3222-3226.	1.3	23
134	Epidemiology and clinical outcome of lower respiratory tract infections by respiratory syncytial virus or parainfluenza virus type 3 in adults receiving treatment for either acute leukemia or severe aplastic anemia: a retrospective single center study. <i>Annals of Hematology</i> , 2015, 94, 1931-1934.	1.8	5
135	Early Education for Early, Integrated Palliative Medicine. <i>Journal of Pain and Symptom Management</i> , 2015, 50, e1-e2.	1.2	2
136	Safety profile of <i>Erwinia</i> asparaginase treatment in adults with newly diagnosed acute lymphoblastic leukemia: a retrospective monocenter study. <i>Leukemia and Lymphoma</i> , 2015, 56, 770-773.	1.3	4
137	Ibrutinib Targets Nurse-like Cells Supporting an Immunosuppressive Phenotype in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 613-613.	1.4	0
138	Endothelin-1 Promotes Survival and Chemoresistance in Chronic Lymphocytic Leukemia B Cells through ETA Receptor. <i>PLoS ONE</i> , 2014, 9, e98818.	2.5	33
139	Genetic PTX3 Deficiency and Aspergillosis in Stem-Cell Transplantation. <i>New England Journal of Medicine</i> , 2014, 370, 421-432.	27.0	265
140	Ruxolitinib for pulmonary extramedullary hematopoiesis in myelofibrosis. <i>Leukemia and Lymphoma</i> , 2014, 55, 2207-2208.	1.3	5
141	An unusual case of B-ALL occurring in a patient with acute promyelocytic leukemia in remission after two hematopoietic SCTs: whose are the leukemic cells?. <i>Bone Marrow Transplantation</i> , 2014, 49, 1237-1238.	2.4	0
142	An unusual case of splenomegaly and increased lactate dehydrogenase heralding acute myeloid leukemia with eosinophilia and RUNX1-MECOM fusion transcripts. <i>Leukemia Research Reports</i> , 2014, 3, 83-85.	0.4	1
143	Long-term molecular remission with persistence of <i>BCR-ABL</i> 1-specific cytotoxic T cells following imatinib withdrawal in an elderly patient with Philadelphia-positive <i>ALL</i> . <i>British Journal of Haematology</i> , 2014, 164, 299-302.	2.5	8
144	Chromosomally Integrated HHV-6. , 2014, , 251-265.		0

#	ARTICLE	IF	CITATIONS
145	Classification of HHV-6A and HHV-6B as distinct viruses. Archives of Virology, 2014, 159, 863-870.	2.1	292
146	Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response. Leukemia Research, 2014, 38, 581-585.	0.8	20
147	Splenomegaly in haematological malignancies and portal hypertension. Presse Medicale, 2014, 43, 1295-1296.	1.9	1
148	Feedbacks and adaptive capabilities of the PI3K/Akt/mTOR axis in acute myeloid leukemia revealed by pathway selective inhibition and phosphoproteome analysis. Leukemia, 2014, 28, 2197-2205.	7.2	60
149	Results of a Multicenter, Controlled, Randomized Clinical Trial Evaluating the Combination of Piperacillin/Tazobactam and Tigecycline in High-Risk Hematologic Patients With Cancer With Febrile Neutropenia. Journal of Clinical Oncology, 2014, 32, 1463-1471.	1.6	55
150	Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement. Cancer, 2014, 120, 1002-1009.	4.1	116
151	ABO blood group and risk of peripheral arterial thrombosis in patients with atrial fibrillation: a single center survey. Journal of Thrombosis and Thrombolysis, 2014, 38, 30-31.	2.1	4
152	High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial. Journal of Clinical Oncology, 2014, 32, 219-228.	1.6	145
153	Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia. Experimental Hematology, 2014, 42, 126-136.e1.	0.4	23
154	Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia. New England Journal of Medicine, 2013, 369, 111-121.	27.0	1,284
155	Successful liver transplantation in a patient with splanchnic vein thrombosis and pulmonary embolism due to polycythemia vera with Jak2v617f mutation and heparin-induced thrombocytopenia. Journal of Thrombosis and Thrombolysis, 2013, 36, 352-354.	2.1	6
156	O blood group is a risk factor for severe mucosal hemorrhage in orally anticoagulated patients. Journal of Thrombosis and Thrombolysis, 2013, 36, 358-360.	2.1	5
157	ABO blood group and risk of coronary artery disease. Journal of Thrombosis and Thrombolysis, 2013, 36, 286-287.	2.1	16
158	O blood group and the risk of major bleeding: a single-center survey. Journal of Thrombosis and Thrombolysis, 2013, 35, 65-66.	2.1	4
159	Early palliative and supportive care in hematology wards. Leukemia Research, 2013, 37, 725-726.	0.8	5
160	A hematology consensus agreement on antifungal strategies for neutropenic patients with hematological malignancies and stem cell transplant recipients. Hematological Oncology, 2013, 31, 117-126.	1.7	21
161	The monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammation. Haematologica, 2013, 98, 1115-1123.	3.5	92
162	Human Herpesvirus 8 (HHV8) Infection and Related Diseases in Italian Transplant Cohorts. American Journal of Transplantation, 2013, 13, 1619-1620.	4.7	8

#	ARTICLE	IF	CITATIONS
163	Trends in Immune Cell Function Assay and Donor-Specific HLA Antibodies in Kidney Transplantation: A 3-Year Prospective Study. American Journal of Transplantation, 2013, 13, 3215-3222.	4.7	17
164	Clinical heterogeneity of <i>de novo</i> 11q deletion chronic lymphocytic leukaemia: prognostic relevance of extent of 11q deleted nuclei inside leukemic clone. Hematological Oncology, 2013, 31, 88-95.	1.7	25
165	Characterization of Specific Immune Responses to Different Aspergillus Antigens during the Course of Invasive Aspergillosis in Hematologic Patients. PLoS ONE, 2013, 8, e74326.	2.5	48
166	Immunity to Polyomavirus BK Infection: Immune Monitoring to Regulate the Balance between Risk of BKV Nephropathy and Induction of Alloimmunity. Clinical and Developmental Immunology, 2013, 2013, 1-6.	3.3	49
167	Rate of complete hematological response of elderly Ph+ acute lymphoblastic leukemia (ALL) patients by sequential use of nilotinib and imatinib: A GIMEMA protocol LAL 1408.. Journal of Clinical Oncology, 2013, 31, 7025-7025.	1.6	1
168	Pathogenetic Mechanisms of Hepatitis C Virus-Induced B-Cell Lymphomagenesis. Clinical and Developmental Immunology, 2012, 2012, 1-9.	3.3	20
169	Impact of early access to a palliative/supportive care intervention on pain management in patients with cancer. Annals of Oncology, 2012, 23, 2016-2020.	1.2	67
170	Physical contact with endothelial cells through $\alpha 1$ - and $\alpha 2$ - integrins rescues chronic lymphocytic leukemia cells from spontaneous and drug-induced apoptosis and induces a peculiar gene expression profile in leukemic cells. Haematologica, 2012, 97, 952-960.	3.5	29
171	How I treat HHV8/KSHV-related diseases in posttransplant patients. Blood, 2012, 120, 4150-4159.	1.4	89
172	Severe Pneumonia Caused by Legionella pneumophila Serogroup 11, Italy. Emerging Infectious Diseases, 2012, 18, 1911-1913.	4.3	6
173	Chromosomally integrated human herpesvirus 6: questions and answers. Reviews in Medical Virology, 2012, 22, 144-155.	8.3	320
174	Atraumatic splenic rupture in patients with myelodysplastic syndromes: Report of a case occurred during treatment with 5-azacitidine and review of the literature. Leukemia Research, 2012, 36, e52-e56.	0.8	3
175	BCR-ABL kinase domain mutations and resistance in Ph+ acute lymphoblastic leukemia from the imatinib to the second-generation TKI era.. Journal of Clinical Oncology, 2012, 30, 6531-6531.	1.6	0
176	Cytarabine-Induced Pulmonary Toxicity in Leukemic Patients. , 2011, , 729-734.		1
177	Massive bleeding: Are we doing our best?. Transfusion and Apheresis Science, 2011, 45, 287-290.	1.0	8
178	May the Indirect Effects of CMV in Transplant Patients be Exerted Through the Reactivation of the Viral Replicative Machinery?. Transplantation, 2011, 92, e49-e51.	1.0	6
179	Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-“positive acute lymphoblastic leukemia. Blood, 2011, 118, 6521-6528.	1.4	395
180	Mucorales-specific T cells emerge in the course of invasive mucormycosis and may be used as a surrogate diagnostic marker in high-risk patients. Blood, 2011, 118, 5416-5419.	1.4	102

#	ARTICLE	IF	CITATIONS
181	Differences in Kaposi sarcoma-associated herpesvirus-specific and herpesvirus-non-specific immune responses in classic Kaposi sarcoma cases and matched controls in Sicily. <i>Cancer Science</i> , 2011, 102, 1769-1773.	3.9	13
182	Chronic eosinophilic leukaemia with ETV6-NTRK3 fusion transcript in an elderly patient affected with pancreatic carcinoma. <i>European Journal of Haematology</i> , 2011, 86, 352-355.	2.2	22
183	Novel polymeric/lipidic hybrid systems (PLHs) for effective Cidofovir delivery: Preparation, characterization and comparative in vitro study with polymeric particles and liposomes. <i>International Journal of Pharmaceutics</i> , 2011, 413, 220-228.	5.2	10
184	A case of JAK2 V617F-positive myelodysplastic/myeloproliferative neoplasm with unusual morphology, resembling acute promyelocytic leukemia-like disorder with a chronic course. <i>Leukemia and Lymphoma</i> , 2011, 52, 2012-2019.	1.3	1
185	CDKN2A/B Alterations Impair Prognosis in Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia Patients. <i>Clinical Cancer Research</i> , 2011, 17, 7413-7423.	7.0	62
186	HHVs AND LYMPHOPROLIFERATIVE DISORDERS. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2011, 3, e2011043.	1.3	11
187	Splenic hyalohyphomycosis, molecularly and immunologically consistent with invasive aspergillosis, in a patient with acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2010, 85, 188-189.	4.1	3
188	Common Vascular Endothelial Growth Factor Variants and Risk for Posttransplant Kaposi Sarcoma. <i>Transplantation</i> , 2010, 90, 337-338.	1.0	2
189	Emergence of BCR-ABL-specific cytotoxic T cells in the bone marrow of patients with Ph+ acute lymphoblastic leukemia during long-term imatinib mesylate treatment. <i>Blood</i> , 2010, 115, 1512-1518.	1.4	45
190	High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study. <i>Annals of Hematology</i> , 2010, 89, 591-596.	1.8	115
191	Cidofovir-loaded liposomes: an intro-study using BCBL-1 cell line as a model for primary effusion lymphoma. <i>European Journal of Pharmaceutical Sciences</i> , 2010, 41, 254-264.	4.0	16
192	Organising pneumonia mimicking invasive fungal disease in patients with leukaemia. <i>European Journal of Haematology</i> , 2010, 85, 76-82.	2.2	7
193	Review Part 3: Human herpesvirus-6 in multiple non-neurological diseases. <i>Journal of Medical Virology</i> , 2010, 82, 1903-1910.	5.0	45
194	Pain and emotional distress in leukemia patients at diagnosis. <i>Leukemia Research</i> , 2010, 34, e67-e68.	0.8	27
195	Is pain in patients with haematological malignancies under-recognised? The results from Italian ECAD-O survey. <i>Leukemia Research</i> , 2010, 34, e334-e335.	0.8	15
196	Adherence to international guidelines for the treatment of invasive aspergillosis in acute myeloid leukaemia: feasibility and utility (SEIFEM-2008B study). <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2013-2018.	3.0	19
197	Immunoliposomal systems targeting primary effusion lymphoma: in vitro study. <i>Nanomedicine</i> , 2010, 5, 1051-1064.	3.3	8
198	The therapeutic response and clinical outcome of adults with ALL1(MLL)/AF4 fusion positive acute lymphoblastic leukemia according to the GIMEMA experience. <i>Haematologica</i> , 2010, 95, 837-840.	3.5	12

#	ARTICLE	IF	CITATIONS
199	Impact of setting of care on pain management in patients with cancer: a multicentre cross-sectional study. <i>Annals of Oncology</i> , 2010, 21, 2088-2093.	1.2	17
200	Translational challenges of human herpesvirus 6 chromosomal integration. <i>Future Microbiology</i> , 2010, 5, 993-995.	2.0	7
201	HHV-6 and atypical lymphoproliferative disorders: are only qualitative molecular examinations sufficient to support a pathogenetic role?. <i>Leukemia and Lymphoma</i> , 2010, 51, 565-567.	1.3	1
202	Naturally Occurring Human Urinary Peptides for Use in Diagnosis of Chronic Kidney Disease. <i>Molecular and Cellular Proteomics</i> , 2010, 9, 2424-2437.	3.8	434
203	Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. <i>Haematologica</i> , 2010, 95, 644-650.	3.5	273
204	Immunological and inflammatory features of Kaposi's sarcoma and other Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8-associated neoplasias. <i>AIDS Reviews</i> , 2010, 12, 40-51.	1.0	21
205	Performance of Tests for Latent Tuberculosis in Different Groups of Immunocompromised Patients. <i>Chest</i> , 2009, 136, 198-204.	0.8	137
206	Persistent hiccups as an adverse event to FLAG-IDA regimen for leukemia. <i>Acta Oncologica</i> , 2009, 48, 932-933.	1.8	3
207	Prescription of opioids in Italy: everything, but the morphine. <i>Annals of Oncology</i> , 2009, 20, 961-962.	1.2	27
208	Changes in T-Cell Responses Against Human Herpesvirus-8 Correlate with the Disease Course of Iatrogenic Kaposi's Sarcoma in a Patient with Undifferentiated Arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2009, 39, 170-175.	3.4	8
209	Prevalence of Human Herpesvirus-6 Chromosomal Integration (CIHHV-6) in Italian Solid Organ and Allogeneic Stem Cell Transplant Patients. <i>American Journal of Transplantation</i> , 2009, 9, 1690-1697.	4.7	40
210	Diagnosis of aspergillosis: Role of proteomics. <i>Current Fungal Infection Reports</i> , 2009, 3, 216-222.	2.6	0
211	Interferon-α may restore sensitivity to tyrosine kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation. <i>British Journal of Haematology</i> , 2009, 146, 227-230.	2.5	4
212	Inflammatory myofibroblastic tumor of the bone marrow. <i>Leukemia Research</i> , 2009, 33, e224-e227.	0.8	0
213	Acute promyelocytic leukemia in very elderly patients: still a clinical challenge. <i>Leukemia and Lymphoma</i> , 2009, 50, 119-121.	1.3	6
214	Indirect Antitumor Effects of Mammalian Target of Rapamycin Inhibitors Against Kaposi Sarcoma in Transplant Patients. <i>Transplantation</i> , 2009, 88, 597-598.	1.0	15
215	Kaposi's sarcoma after liver transplantation. <i>Journal of Cancer Research and Clinical Oncology</i> , 2008, 134, 653-658.	2.5	40
216	Acute appendicitis in adult neutropenic patients with hematologic malignancies. <i>Bone Marrow Transplantation</i> , 2008, 42, 701-703.	2.4	18

#	ARTICLE	IF	CITATIONS
217	BK virus infection and neurologic dysfunctions in a patient with lymphoma treated with chemotherapy and rituximab. <i>European Journal of Haematology</i> , 2008, 81, 244-245.	2.2	12
218	Assessment of <i>Aspergillus</i> -Specific T Cells for Diagnosis of Invasive Aspergillosis in a Leukemic Child with Liver Lesions Mimicking Hepatosplenic Candidiasis. <i>Vaccine Journal</i> , 2008, 15, 1625-1628.	3.1	14
219	HHV-6A in Syncytial Giant-Cell Hepatitis. <i>New England Journal of Medicine</i> , 2008, 359, 593-602.	27.0	99
220	A possible role for low-dose cyclosporine in refractory immune thrombocytopenic purpura. <i>Haematologica</i> , 2008, 93, 1113-1115.	3.5	15
221	Changes in the Immune Responses Against Human Herpesvirus-8 in the Disease Course of Posttransplant Kaposi Sarcoma. <i>Transplantation</i> , 2008, 86, 738-744.	1.0	62
222	Parvoviruses in Blood Donors and Transplant Patients, Italy. <i>Emerging Infectious Diseases</i> , 2008, 14, 185-186.	4.3	25
223	Line Treatment of Adult Ph+ Acute Lymphoblastic Leukemia (ALL) Patients. Final Results of the GIMEMA LAL1205 Study. <i>Blood</i> , 2008, 112, 305-305.	1.4	21
224	Reply to: [Efficacy of cyclosporine as a single agent therapy in chronic idiopathic thrombocytopenic purpura". <i>Haematologica</i> 2008; 93:e61]. <i>Haematologica</i> , 2008, 93, e63-e63.	3.5	0
225	Cytarabine-related lung infiltrates on high resolution computerized tomography: a possible complication with benign outcome in leukemic patients. <i>Haematologica</i> , 2007, 92, e85-e90.	3.5	29
226	ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. <i>Blood</i> , 2007, 109, 5473-5476.	1.4	46
227	<i>Helicobacter pylori</i> infection and chronic immune thrombocytopenic purpura: long-term results of bacterium eradication and association with bacterium virulence profiles. <i>Blood</i> , 2007, 110, 3833-3841.	1.4	84
228	A database of naturally occurring human urinary peptides and proteins for use in clinical applications. <i>Nature Precedings</i> , 2007, , .	0.1	0
229	Characterization of B cell lymphoma in patients with Sjögren's syndrome and hepatitis C virus infection. <i>Arthritis and Rheumatism</i> , 2007, 57, 161-170.	6.7	66
230	Epstein-Barr virus associated pneumonia in an adult patient with severe aplastic anaemia: Resolution after the transient withdrawal of cyclosporine. <i>American Journal of Hematology</i> , 2007, 82, 944-946.	4.1	4
231	May the correlation between Kit-D816 mutation and AML1-ETO level change the use of prognostic factors in t(8;21) AML?. <i>Leukemia Research</i> , 2007, 31, 269-271.	0.8	1
232	Diagnosis of invasive aspergillosis by tracking <i>Aspergillus</i> -specific T cells in hematologic patients with pulmonary infiltrates. <i>Leukemia</i> , 2007, 21, 578-581.	7.2	24
233	B cells and Herpesviruses: A model of lymphoproliferation. <i>Autoimmunity Reviews</i> , 2007, 7, 132-136.	5.8	25
234	Fatal hemophagocytic syndrome related to active human herpesvirus-8/Kaposi sarcoma-associated herpesvirus infection in human immunodeficiency virus-negative, non-transplant patients without related malignancies. <i>European Journal of Haematology</i> , 2007, 78, 361-364.	2.2	20



#	ARTICLE	IF	CITATIONS
235	Dasatinib as Front-Line Monotherapy for the Induction Treatment of Adult and Elderly Ph+ Acute Lymphoblastic Leukemia (ALL) Patients: Interim Analysis of the GIMEMA Prospective Study LAL1205.. Blood, 2007, 110, 7-7.	1.4	16
236	Ocular involvement as first sign of isolated CNS relapse in diffuse large B-cell lymphoma. Lancet Oncology, The, 2006, 7, 274.	10.7	1
237	KSHV/HHV-8 Infection of Tubular Epithelial Cells in Transplantation Kidney. Transplantation, 2006, 82, 851-852.	1.0	7
238	More on: platelet count and the Use of Recombinant Factor VIIa for the treatment of Bleeding Complications after Hematopoietic Stem Cell Transplantation. Journal of Thrombosis and Haemostasis, 2006, 4, 288-288.	3.8	2
239	Diagnosis of occult tuberculosis in hematological malignancy by enumeration of antigen-specific T cells. Leukemia, 2006, 20, 379-381.	7.2	17
240	Kaposi's sarcoma triggered by endogenous HHV-8 reactivation after non-myeloablative allogeneic haematopoietic transplantation. European Journal of Haematology, 2006, 76, 342-347.	2.2	29
241	Isolated extramedullary relapse after autologous bone marrow transplantation for acute myeloid leukemia: Case report and review of the literature. American Journal of Hematology, 2006, 81, 45-50.	4.1	17
242	Human Herpesvirus 6 Latency Characterized by High Viral Load: Chromosomal Integration in Many, but Not All, Cells. Journal of Infectious Diseases, 2006, 194, 1020-1021.	4.0	25
243	A non-chemotherapy treatment of a primary effusion lymphoma: durable remission after intracavitary cidofovir in HIV negative PEL refractory to chemotherapy. Annals of Oncology, 2006, 17, 1849-1850.	1.2	67
244	A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. Blood, 2005, 105, 3434-3441.	1.4	178
245	Suppressive effect of human herpesvirus-8/Kaposi sarcoma-associated herpesvirus on in vitro colony formation of hematopoietic progenitor cells. Leukemia Research, 2005, 29, 951-953.	0.8	5
246	Pneumonia in acute leukaemia: blossoming culprits. British Journal of Haematology, 2005, 128, 411-411.	2.5	0
247	Treatment of herpesvirus associated primary effusion lymphoma with intracavity cidofovir. Leukemia, 2005, 19, 473-476.	7.2	97
248	Herpes simplex virus pneumonia during standard induction chemotherapy for acute leukemia: case report and review of literature. Leukemia, 2005, 19, 2019-2021.	7.2	16
249	Infectious agents and human immune diseases: Lessons from Helicobacter pylori. American Journal of Medicine, 2005, 118, 420-421.	1.5	13
250	Efficacy of imatinib mesylate as maintenance therapy in adults with acute lymphoblastic leukemia in first complete remission. Haematologica, 2005, 90, 1275-7.	3.5	5
251	Thrombotic complications associated with thalidomide in multiple myeloma: an old problem with new questions and quandaries in decision-making. Thrombosis and Haemostasis, 2004, 91, 834-836.	3.4	5
252	Cardiac Involvement in Malignancies. Journal of Clinical Oncology, 2004, 22, 2742-2744.	1.6	2



#	ARTICLE	IF	CITATIONS
253	Gemtuzumab Ozogamicin for Relapsed and Refractory Acute Myeloid Leukemia and Myeloid Sarcomas. Leukemia and Lymphoma, 2004, 45, 1791-1795.	1.3	67
254	Is it now the time to update treatment protocols for lymphomas with new anti-virus systems?. Leukemia, 2004, 18, 1572-1575.	7.2	5
255	Myocardial ischemia in a patient with acute lymphoblastic leukemia during l-asparaginase therapy. European Journal of Haematology, 2004, 72, 71-72.	2.2	8
256	A t(11;20)(p15;q11) may identify a subset of nontherapy-related acute myelocytic leukemia. Cancer Genetics and Cytogenetics, 2004, 149, 164-168.	1.0	8
257	An IELSG International Survey of Primary Effusion Lymphoma (PEL).. Blood, 2004, 104, 3265-3265.	1.4	2
258	Helicobacter pylori and Idiopathic Thrombocytopenic Purpura. Annals of Internal Medicine, 2004, 141, 820.	3.9	1
259	Necrotising dermatitis in refractory acute myeloid leukaemia. European Journal of Haematology, 2003, 71, 464-465.	2.2	2
260	Leukaemic pulmonary infiltrates in adult acute myeloid leukaemia: a high-resolution computerized tomography study. British Journal of Haematology, 2003, 120, 1058-1061.	2.5	37
261	Late occurrence of hepatic veno-occlusive disease following gemtuzumab ozogamicin: successful treatment with defibrotide. British Journal of Haematology, 2003, 123, 752-753.	2.5	13
262	Mysticism to medicine. Nature Medicine, 2003, 9, 507-507.	30.7	0
263	Reply to "KSHV reactivation in post-transplant Kaposi sarcoma". Nature Medicine, 2003, 9, 986-986.	30.7	0
264	Post-transplant Kaposi sarcoma originates from the seeding of donor-derived progenitors. Nature Medicine, 2003, 9, 554-561.	30.7	205
265	Acquired haemophilia in HIV negative, HHV-8 positive multicentric Castleman's disease: a case report. European Journal of Haematology, 2003, 70, 181-182.	2.2	29
266	Immune Thrombocytopenic Purpura and Helicobacter pylori Infection. Archives of Internal Medicine, 2003, 163, 120.	3.8	4
267	Human Herpesvirus 8-Associated Diseases in Solid-Organ Transplantation: Importance of Viral Transmission from the Donor. Clinical Infectious Diseases, 2003, 37, 606-607.	5.8	26
268	Unsuccessful Treatment with Voriconazole of a Brain Abscess due to Cladophialophora bantiana. Scandinavian Journal of Infectious Diseases, 2003, 35, 892-893.	1.5	36
269	Skin Cancers after Organ Transplantation. New England Journal of Medicine, 2003, 349, 612-614.	27.0	12
270	HHV-8 Infection in the Transplantation Setting: A Concern Only for Solid Organ Transplant Patients?. Leukemia and Lymphoma, 2002, 43, 517-522.	1.3	23

#	ARTICLE	IF	CITATIONS
271	Severe pancytopenia and hemophagocytosis after HHV-8 primary infection in a renal transplant patient successfully treated with foscarnet <sup>1</sup> . Transplantation, 2002, 74, 131-133.	1.0	81
272	Long-term salvage therapy with cyclosporin A in refractory idiopathic thrombocytopenic purpura. Blood, 2002, 99, 1482-1485.	1.4	94
273	Mixed warm and cold autoimmune hemolytic anemia: complete recovery after 2 courses of rituximab treatment. Blood, 2002, 99, 3478-3479.	1.4	35
274	Idiopathic thrombocytopenic purpura, Helicobacter pylori infection, and HLA class II alleles. Blood, 2002, 100, 1925-1927.	1.4	39
275	“Gloves and socks” <sup>TM</sup> papular purpuric syndrome following primary infection with parvovirus B19: A link between dermatologists and haematologists. British Journal of Haematology, 2002, 117, 773-774.	2.5	1
276	Helicobacter pylori infection and idiopathic thrombocytopenic purpura. British Journal of Haematology, 2002, 118, 1198-1199.	2.5	28
277	Human herpesvirus 8-associated primary effusion lymphoma in HIV-patients: a clinicopathologic variant resembling classic Kaposi's sarcoma. Haematologica, 2002, 87, 339-43.	3.5	32
278	Immunoglobulin Gene Mutations and Frequent Use of VH1-69 and VH4-34 Segments in Hepatitis C Virus-Positive and Hepatitis C Virus-Negative Nodal Marginal Zone B-Cell Lymphoma. American Journal of Pathology, 2001, 159, 253-261.	3.8	148
279	Helicobacter pylori eradication can induce platelet recovery in idiopathic thrombocytopenic purpura. Blood, 2001, 97, 812-814.	1.4	246
280	BCR-ABL rearrangement is not detectable in essential thrombocythemia. Blood, 2001, 97, 2187-2189.	1.4	21
281	Angiogenesis in multiple myeloma: correlation between in vitro endothelial colonies growth (CFU-En) and clinical “biological features. Leukemia, 2001, 15, 171-176.	7.2	29
282	PCR with degenerate primers for highly conserved DNA polymerase gene of the herpesvirus family shows neither human herpesvirus 8 nor a related variant in bone marrow stromal cells from multiple myeloma patients. , 2000, 86, 76-82.		14
283	Late-Appearing PML/RAR $\alpha$ Fusion Transcript with Coincidental t(12;13)(p13.2;q14) in Acute Promyelocytic Leukemia Lacking the t(15;17) Cytogenetic Anomaly. Cancer Genetics and Cytogenetics, 2000, 119, 121-126.	1.0	7
284	Nonmalignant disease associated with human herpesvirus 8 reactivation in patients who have undergone autologous peripheral blood stem cell transplantation. Blood, 2000, 96, 2355-2357.	1.4	46
285	Molecular evidence of organ-related transmission of Kaposi sarcoma “associated herpesvirus or human herpesvirus-8 in transplant patients. Blood, 2000, 96, 3279-3281.	1.4	92
286	Detection of Circulating Tumor Cells by Reverse Transcriptase Polymerase Chain Reaction of Maspin in Patients With Breast Cancer Undergoing Conventional-Dose Chemotherapy. Journal of Clinical Oncology, 2000, 18, 1914-1920.	1.6	48
287	SPECIAL DEPARTMENTS. Journal of Clinical Oncology, 2000, 18, 3196-3197.	1.6	8
288	Bone Marrow Failure Associated with Human Herpesvirus 8 Infection after Transplantation. New England Journal of Medicine, 2000, 343, 1378-1385.	27.0	224

#	ARTICLE	IF	CITATIONS
289	Gestational thrombocytopenia. Lancet, The, 2000, 356, 1355.	13.7	0
290	Nonmalignant disease associated with human herpesvirus 8 reactivation in patients who have undergone autologous peripheral blood stem cell transplantation. Blood, 2000, 96, 2355-2357.	1.4	14
291	Molecular evidence of organ-related transmission of Kaposi sarcoma-associated herpesvirus or human herpesvirus-8 in transplant patients. Blood, 2000, 96, 3279-3281.	1.4	34
292	The oncogenic 30 and 69 bp deletion variants of the EBV LMP-1 gene are common in HIV-negative lymphoproliferations, both malignant and benign. Annals of Oncology, 1999, 10, 467-469.	1.2	6
293	Expression of Cell-Homologous Genes of Human Herpesvirus-8 in Human Immunodeficiency Virus-Negative Lymphoproliferative Diseases. Blood, 1999, 94, 2931-2933.	1.4	22
294	Human herpesvirus-8 infection in hemodialysis patients from northern Italy. Kidney International, 1999, 55, 340.	5.2	7
295	Lack of confirmation of an association between HTLV-I infection and myelodysplastic syndrome. British Journal of Haematology, 1999, 105, 1146-1147.	2.5	5
296	Fine mapping of an apparently targeted latent human herpesvirus type 6 integration site in chromosome band 17p13.3. , 1999, 58, 69-75.		43
297	Variability and evolution of Kaposi's sarcoma-associated herpesvirus in Europe and Africa. Aids, 1999, 13, 1165-1176.	2.2	107
298	Human Herpesvirus 6 Latently Infects Early Bone Marrow Progenitors In Vivo. Journal of Virology, 1999, 73, 754-759.	3.4	122
299	Occurrence of a novel t(11;19)(q13;q13.3) in complete remission of acute promyelocytic leukemia. Cancer Genetics and Cytogenetics, 1998, 101, 35-38.	1.0	5
300	Chronic myeloid leukemia with thrombocytopenic onset may be associated with different BCR/ABL variant transcripts. Cancer Genetics and Cytogenetics, 1998, 101, 75-77.	1.0	9
301	Absence of a directly causative role for human herpesvirus 7 in human lymphoma and a review of human herpesvirus 6 in human malignancy. Annals of Hematology, 1998, 77, 275-278.	1.8	28
302	Integration of human herpesvirus 6 genome in human chromosomes. Lancet, The, 1998, 352, 1707.	13.7	24
303	Expression of Human Herpesvirus-6 Antigens in Benign and Malignant Lymphoproliferative Diseases. American Journal of Pathology, 1998, 153, 815-823.	3.8	145
304	Human Herpesvirus 8 Seroprevalence in Blood Donors and Lymphoma Patients From Different Regions of Italy. Journal of the National Cancer Institute, 1998, 90, 395-397.	6.3	228
305	Polymerase Chain Reaction Detection of Human Herpesvirus 8 Sequences in Primary Central Nervous System Lymphomas. Journal of Infectious Diseases, 1998, 177, 520-520.	4.0	2
306	Clinico-pathological characterization of hepatitis C virus-related B-cell non-Hodgkin's lymphomas without symptomatic cryoglobulinemia. Annals of Oncology, 1998, 9, 495-498.	1.2	93

#	ARTICLE	IF	CITATIONS
307	Hepatitis C Virus Genotype Distribution in B-Cell Non-Hodgkin Lymphoma. Annals of Internal Medicine, 1998, 128, 602.	3.9	19
308	Might Essential Thrombocythemia Carry Ph Anomaly?. Blood, 1998, 91, 3084-3085.	1.4	19
309	Kaposi's Sarcoma-Associated Herpesvirus Infection and Multiple Myeloma. Science, 1997, 278, 1969-1973.	12.6	92
310	Relationship Between BCR/ABL Fusion Proteins and Leukemia Phenotype. Blood, 1997, 89, 3889-3889.	1.4	11
311	Human herpesvirus 6 (HHV-6) ORF-1 transactivating gene exhibits malignant transforming activity and its protein binds to p53. Oncogene, 1997, 14, 359-367.	5.9	93
312	Human herpesvirus-6 reactivation in a longitudinal study of two HIV-1 infected patients. , 1997, 51, 259-264.		13
313	Hepatitis C virus-induced leuko-thrombocytopenia and haemolysis. , 1997, 53, 182-184.		10
314	HHV-8-associated primary cerebral B-cell lymphoma in HIV-negative patient after long-term steroids. Lancet, The, 1996, 347, 980.	13.7	18
315	Frequency and distribution of herpesvirus-like DNA sequences (KSHV) in different stages of classic Kaposi's sarcoma and in normal tissues from an Italian population. , 1996, 66, 427-431.		39
316	Additional neoplasms and HCV infection in low-grade lymphoma of MALT type. British Journal of Haematology, 1996, 94, 373-375.	2.5	121
317	P53 Gene Mutations in Chronic Myelogenous Leukemia Medullary and Extramedullary Blast Crisis. Leukemia and Lymphoma, 1996, 24, 175-182.	1.3	8
318	Human Herpesvirus 8 and Interstitial Pneumonitis in an HIV-Negative Patient. New England Journal of Medicine, 1996, 335, 351-352.	27.0	12
319	Frequency of Human Herpesvirus Type 6 (HHV-6) Genome Detection in AIDS-Related Lymphoproliferative Disorders. Journal of Acquired Immune Deficiency Syndromes, 1995, 9, 311.	0.3	6
320	Geographic sequence variation of latent membrane protein 1 gene of Epstein-Barr virus in Hodgkin's lymphomas. Journal of Medical Virology, 1995, 45, 183-191.	5.0	12
321	Targeted integration of human herpesvirus 6 in the p arm of chromosome 17 of human peripheral blood mononuclear cells in vivo. Journal of Medical Virology, 1995, 46, 178-188.	5.0	117
322	Human herpesvirus-6: A survey of presence and distribution of genomic sequences in normal brain and neuroglial tumors. Journal of Medical Virology, 1995, 47, 105-111.	5.0	84
323	Spontaneous loss of ph chromosome with maintenance of clonal hemopoiesis in an untreated patient with myeloproliferative disease and a long survival. Genes Chromosomes and Cancer, 1995, 12, 237-240.	2.8	1
324	Human Herpesvirus-6 Genome in Acute Lymphoblastic Leukemia: Evidence against an Etiologic Relationship. Acta Haematologica, 1995, 94, 169-172.	1.4	12

#	ARTICLE	IF	CITATIONS
325	HUMAN HERPESVIRUS 6 (HHV-6) IN BLOOD DONORS. British Journal of Haematology, 1995, 89, 943-945.	2.5	6
326	Double P53 Point Mutation in Extramedullar Blast Crisis of Chronic Myelogenous Leukemia. Leukemia and Lymphoma, 1994, 16, 171-175.	1.3	4
327	Human Herpesvirus 6 Infection in Normal Human Brain Tissue. Journal of Infectious Diseases, 1994, 169, 943-944.	4.0	148
328	Three cases of human herpesvirus-6 latent infection: Integration of viral genome in peripheral blood mononuclear cell DNA. Journal of Medical Virology, 1993, 40, 44-52.	5.0	169
329	Frequent detection of human herpesvirus-6 sequences by polymerase chain reaction in paraffin-embedded lymph nodes from patients with angioimmunoblastic lymphadenopathy and angioimmunoblastic lymphadenopathy-like lymphoma. Leukemia Research, 1993, 17, 1003-1011.	0.8	52
330	Characterization of Human Herpesvirus 6 Genomes from Cases of Latent Infection in Human Lymphomas and Immune Disorders. Journal of Infectious Diseases, 1993, 168, 1074-1075.	4.0	16
331	Human herpesvirus 6 and multiple sclerosis: survey of anti-HHV-6 antibodies by immunofluorescence analysis and of viral sequences by polymerase chain reaction.. Journal of Neurology, Neurosurgery and Psychiatry, 1993, 56, 917-919.	1.9	99
332	Reactivation of Epstein-Barr virus in Sjögren's syndrome. Seminars in Immunopathology, 1991, 13, 217-231.	4.0	49